Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy By: TalkMarkets June 03, 2020 at 12:50 PM EDT Geoffrey Porges upgraded Gilead Sciences from Market Perform to Outperform and raised the price target from $85 to $94. Read More >> Related Stocks: Arcus Biosciences Inc Gilead Sciences